Giant Biogene Holding Co., Ltd. (02367.HK) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	11.4B	5.5B	5.5B	3.5B	2.4B
Cost of Revenue	2.2B	1.1B	991.9M	577.0M	369.2M
Gross Profit	9.2B	4.4B	4.5B	2.9B	2.0B
Operating Expenses
R&D Expense	191.5M	88.8M	106.5M	75.0M	44.0M
SG&A Expense	4.8B	2.2B	2.2B	1.3B	817.4M
General & Admin Expense	253.4M	168.5M	150.5M	96.7M	111.1M
Selling & Marketing Expense	3.2B	2.1B	2.0B	1.2B	706.4M
Other Expenses	(27.4M)	—	(27.0M)	(53.9M)	(44.2M)
Total Operating Expenses	4.9B	2.3B	2.2B	1.3B	817.3M
Cost and Expenses	7.1B	3.4B	3.2B	1.9B	1.2B
Operating Income (EBIT)	4.3B	2.1B	2.3B	1.7B	1.1B
Non-Operating
Interest Income	353.2M	167.7M	111.3M	47.5M	13.2M
Interest Expense	347.6K	302.0K	239.0K	112.0K	21.0K
Net Interest Income	352.8M	167.4M	111.1M	47.4M	13.1M
Other Non-Op Income/Expense	475.9M	229.5M	149.1M	80.2M	44.6M
Non-Operating Income (excl Interest)	30.7M	—	30.7M	(80.3M)	—
EBT (Pre-Tax Income)	4.7B	2.4B	2.5B	1.7B	1.2B
Income Tax Expense	810.3M	435.6M	396.0M	296.9M	176.2M
Bottom Line
Net Income	3.9B	1.9B	2.1B	1.5B	1.0B
Earnings from Cont. Ops	3.9B	1.9B	2.1B	1.4B	1.0B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	3.9B	1.9B	2.1B	1.5B	1.0B
Per Share
Basic EPS	HK$3.81	HK$1.83	HK$2.10	HK$1.49	HK$0.99
Diluted EPS	HK$3.77	HK$1.81	HK$2.06	HK$1.48	HK$0.98
Revenue Per Share	HK$10.85	HK$5.22	HK$5.53	HK$3.59	HK$2.42
Shares
Basic Shares Outstanding	1.1B	1.1B	1.0B	980.9M	976.0M
Diluted Shares Outstanding	1.1B	1.1B	1.0B	982.7M	1.0B
Profitability Metrics
EBITDA	4.4B	2.2B	2.3B	1.8B	1.2B
D&A	132.0M	74.2M	31.6M	34.2M	27.6M
EBIT	4.2B	2.1B	2.3B	1.7B	1.2B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026